Invivyd’s study found fewer short-term side effects with its antibody and higher antibody levels when paired with the vaccine. This supports its planned FDA application, though approval and proof that it prevents illness are still ahead.
These results give Invivyd a stronger case for seeking FDA approval. The study found fewer short-term side effects with its antibody and higher antibody levels with the combined treatment. The FDA has not approved it, and a later study still needs to check whether it prevents illness.
The report compares Pfizer’s vaccine alone with Invivyd’s antibody and the combined treatment. The combination showed fewer short-term side effects and higher antibody levels, but the story reports no new agreement or change in Pfizer’s sales.
The report compares BioNTech’s vaccine alone with Invivyd’s antibody and the combined treatment. The combination showed fewer short-term side effects and higher antibody levels, but the story reports no new agreement or change in BioNTech’s sales.
Follow Invivyd Inc. (IVVD) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for IVVD